Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | BLFS | Common Stock | Award | +395K | +828.09% | 443K | Oct 19, 2023 | Direct | F1, F2 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | BLFS | Restricted Stock Award | Award | $0 | +395K | $0.00 | 395K | Oct 19, 2023 | Common Stock | 395K | $0.00 | Direct | F3 |
Id | Content |
---|---|
F1 | The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of their employment agreement. |
F2 | This reflects the total amount beneficially owned by the reporting person as of October 19, 2023. Previous Form 4's filed by the reporting person before October 19, 2023 did not reflect the acquisition of 2,421 shares. |
F3 | The restricted stock was granted pursuant to the Executive Employment Agreement. The restricted stock will vest in equal annual installments so long as the reporting owner remains employed by the registrant through January 1, 2027. |